Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Potash Corp./Saskatchewan (USA) (POT) Earnings Aren’t Growing

Potash Corp./Saskatchewan (USA) (NYSE:POT) will release its quarterly report on Thursday, and given the increasing importance of fertilizers to produce enough food to feed the world’s growing population, you’d expect that the company would have strong financial results. Yet the stock has been in the doldrums for years now, and Potash Corp./Saskatchewan (USA) (NYSE:POT) earnings look poised to post another substantial year-over-year decline that will prove frustrating for bulls on the stock.
Potash Corp./Saskatchewan (USA) (NYSE:POT)

During the commodity boom from 2004 to early 2008, Potash Corp./Saskatchewan (USA) (NYSE:POT) and its peers became household names among investors, with amazing growth prospects as they sought to help boost farm productivity across the world. But a combination of the financial crisis and the entrance of rival fertilizer companies into the agricultural space helped reverse Potash Corp./Saskatchewan (USA) (NYSE:POT)’s fortunes. Can the potash maker fight back? Let’s take an early look at what’s been happening with Potash Corp./Saskatchewan (USA) (NYSE:POT) over the past quarter and what we’re likely to see in its quarterly report.

Stats on PotashCorp

Analyst EPS Estimate $0.81
Change From Year-Ago EPS (20%)
Revenue Estimate $2.19 billion
Change From Year-Ago Revenue (3.7%)
Earnings Beats in Past Four Quarters 1

Source: Yahoo! Finance.

Will Potash Corp./Saskatchewan (USA) (NYSE:POT) earnings keep withering in the sun?
Analysts still don’t have much faith in PotashCorp earnings, having pruned their June-quarter estimates for the fertilizer company by $0.08 per share and knocking a full dime from full-year 2013 figures. The stock has continued its lackadaisical behavior, rising less than 2% since mid-April.

Early in the quarter, it seemed as though PotashCorp would finally make a turn higher. Even though potash prices fell from more than $455 per ton last year to $390 at the end of March, PotashCorp managed to post 13% higher profits during the first quarter than in the year-ago period, with a 78% jump in potash sales volumes as the company managed to work down some of its inventory. The company followed up its earnings report a couple weeks later with a 25% dividend hike, showing its confidence in the sustainability of its profit growth.

Part of the reason for the turnaround is the reversal of fortune in the fertilizer markets. Both PotashCorp and fellow potash and phosphate fertilizer producer Mosaic Co (NYSE:MOS) benefited from solid contracts with overseas buyers in hot areas like China and India, leading to a big improvement over last year’s strained relationships with emerging-market buyers. By contrast, rivals CF Industries Holdings, Inc. (NYSE:CF) and Agrium Inc. (USA) (NYSE:AGU), which benefited last year from relative strength in the North American market, have seen their prospect shrivel up due to cold, wet weather this spring.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.